Evidence map›Paper›PMID 41262981›Full record

ArticlePNAS nexus2025

Molecular simulations meet personalized medicine: The mechanism of action of CLC-5 antiporter and the origin of Dent's disease.

Veronica Macaluso, Carles Pérez, Robert Soliva, Yvonne Westermaier, Lucía Díaz, Miłosz Wieczór, Modesto Orozco

Abstract read
In one paragraph

Article in PNAS nexus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Veronica MacalusoInstitute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, C/ Baldiri Reixac 10, 08028 Barcelona, Spain.
Carles PérezNostrum Biodiscovery, Av. de Josep Tarradellas 8-10, 08029 Barcelona, Spain.ORCID https://orcid.org/0000-0002-2876-0947
Robert SolivaNostrum Biodiscovery, Av. de Josep Tarradellas 8-10, 08029 Barcelona, Spain.ORCID https://orcid.org/0000-0003-0628-4342
Yvonne WestermaierNostrum Biodiscovery, Av. de Josep Tarradellas 8-10, 08029 Barcelona, Spain.ORCID https://orcid.org/0000-0002-0462-8650
Lucía DíazNostrum Biodiscovery, Av. de Josep Tarradellas 8-10, 08029 Barcelona, Spain.ORCID https://orcid.org/0000-0001-8850-2571
Miłosz WieczórInstitute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, C/ Baldiri Reixac 10, 08028 Barcelona, Spain.ORCID https://orcid.org/0000-0003-4990-8629
Modesto OrozcoInstitute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, C/ Baldiri Reixac 10, 08028 Barcelona, Spain.ORCID https://orcid.org/0000-0002-8608-3278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ClC-5 is a Cl-/H+ antiporter crucial for the homeostasis of the entire organism, and whose functional deficiencies cause pathologies such as Dent's disease, a rare genetic disorder that can have lethal consequences. While the clinical aspects of the pathology are known, its molecular basis is elusive, which hampers the development of potential therapies. We present here a systematic study, where we explore the mechanism of transport of ClC-5, deciphering the choreography of structural changes required for the transport of chloride ions and protons in opposing directions. Once the mechanism is determined, we explore how the 523ΔVal deletion linked to Dent's disease hampers the correct functioning of the transporter, despite having a very minor structural impact. Our study highlights how state-of-the-art simulation methods can shed light on the origin of rare diseases and explore targets for personalized medicine.

Identifiers

PMID41262981
PMCPMC12624513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.